Cell & Gene Therapy Manufacturing Services Market Size Worth US$ 70.7 Billion by 2032, Amid Rising Clinical Trials | Research by SNS Insider [Yahoo! Finance]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Yahoo! Finance
Pune, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Cell & Gene Therapy Manufacturing Services Market Analysis: “The is experiencing rapid growth, with projections indicating a rise from USD 11.4 billion in 2023 to USD 70.7 billion by 2032. This impressive expansion, representing a Compound Annual Growth Rate (CAGR) of 22.4% from 2024 to 2032, is fueled by a surge in clinical trials, technological advancements, and an increasing demand for scalable manufacturing solutions.” Market Overview The Cell & Gene Therapy Manufacturing Services Market is witnessing dynamic evolution due to the escalating demand for cell and gene-based therapies. Currently, over 360 clinical trials are underway for CAR-T cell therapies alone, highlighting substantial investment in the development and scaling of production processes. The industry is rapidly adapting to meet this growing demand, with a focus on innovations in viral vector production, cell culture optimization, and bioprocessing technology to enhance
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results CallBusiness Wire
- bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire
- bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- bluebird bio, Inc. (NASDAQ: BLUE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride [Seeking Alpha]Seeking Alpha
BLUE
Sec Filings
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- 11/8/24 - Form 4
- BLUE's page on the SEC website